An observational study in Diabete Type 1, sponsored by University Hospital, Toulouse. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by University Hospital, Toulouse · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Feeding and Eating Disorders with a site in France — 11 open to participants now, 14 under way, none of them phase 3. Feeding and Eating Disorders · France.
Among the 49 studies in Feeding and Eating Disorders with a site in France, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2025, is one of 29 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 45th registered.
645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.
Browse Feeding and Eating Disorders studies →11 of the 49 studies in Feeding and Eating Disorders with a site in France are open now. Recruiting first, the newest first:
Universite du Littoral Cote d'Opale · Sites in France
Ages 18+
Centre Hospitalier Esquirol · Sites in France
Ages 18–65
Centre Hospitalier St Anne · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–60 · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 102 across 177 observational studies indexed under Feeding and Eating Disorders.
Median enrollment 76 across the 20 interventional studies, 100 across the 29 observational. Of the 29 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 49 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 1 study filed under Feeding and Eating Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Feeding and Eating Disorders with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770089University Hospital, CaenVideoconferencing Adapted Physical Activity in Anorexia Nervosa: a Pilot Study | 2026-12-01 |
| NCT07151924University Hospital, ToulouseEating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy | 2027-02-28 |
| NCT07411807Centre Hospitalier St AnneStudy of the Effectiveness of a Systematic Minimal Early Intervention on Care Engagement in Adults With Eating Disorders Requesting Specialized Treatment. | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Feeding and Eating Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of eating disorders is particularly high among people with type 1 diabetes (T1D). These abnormalities, such as "diabulimia," are frequently responsible for poor insulin therapy management and, consequently, chronic glycemic imbalance, exposing them to an increased risk of complications. Their detection and management unfortunately remain insufficient in current practice.
However, to date, no study has addressed the question of the prevalence and impact of eating disorders in this context. Our research hypotheses are therefore as follows:
Patients clinical characteristics, glycemic monitoring parameters ad questionnaires answers will be recorded. The prevalence of eating disorders will be calculated, and the association between the presence of these abnormalities and baseline clinical characteristics and glycemic control parameters will be analyzed.
The prevalence of eating disorders (EDs) and problematic eating behaviors (PEBs) is particularly high among people with type 1 diabetes (T1D), affecting 20 to 50% of women and 5 to 25% of men among young patients. These abnormalities, such as "diabulimia," are frequently responsible for poor insulin therapy management and, consequently, chronic glycemic imbalance, exposing them to an increased risk of complications. Their detection and management unfortunately remain insufficient in current practice.
The treatment of T1D is currently undergoing a veritable technological revolution linked to the arrival of the first semi-automated insulin therapy devices (or closed loop, LF). The use of these devices most often makes it possible to achieve recommended glycemic control targets (HbA1c, continuous glucose monitoring [CGM] data), reduce glycemic variability, and avoid hypoglycemia. Insulin administration is based on the data transmitted: food intake and quantity of carbohydrates consumed. The role of dietitians is therefore crucial in the therapeutic education of patients and the care pathway imposed by the initiation of this new treatment method. It is likely that many patients initiating automated insulin therapy with BF present an eating disorder or CAP that may interfere with the management of the device.
However, to date, no study has addressed the question of the prevalence and impact of eating disorders and CAP in this context. In the absence of available data, national and international recommendation texts dedicated to insulin therapy with BF do not specify appropriate conduct for patients presenting with these eating disorders. Our research hypotheses are therefore as follows:
Patients clinical characteristics and glycemic monitoring parameters (HbA1c and CGM data), available as part of routine care, will be recorded in an electronic case report (REDCap software). The mSCOFF and QACD questionnaires will be administered during the dietary interview preceding BF device implantation, and responses will be collected. The prevalence of eating disorders will be calculated, and the association between the presence of these abnormalities and baseline clinical characteristics and glycemic control parameters will be analyzed.
The care pathway established for initiating BF treatment requires a follow-up medical consultation at 3 months, followed by a consultation at 6 months. As part of the study, visits at 3 months (12 ± 2 weeks) and 6 months (24 ± 4 weeks) will be scheduled and will include an interview with a dietitian, to collect glycemic control parameters (at 3 and 6 months), measure body weight (at 3 and 6 months), and repeat the mSCOFF and QACD questionnaires (at 6 months). Data on the evolution of glycemic control and variability parameters, weight and mSCOFF and QACD scores will be analyzed in the overall study population, then according to the existence or not of disturbances in eating behavior at inclusion.
patients with type 1 diabetes for whom closed-loop insulin therapy has been recommended
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with type 1 diabete with closed-loop therapy
Other: Questionnaires answers · Other: Biological assessment
Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.
Collection of HbA1c level and continuous glucose monitoring data
Prevalence of eating disorders
The primary outcome measure for establishing the prevalence of eating disorders is a composite outcome measure based on determining the existence of eating disorders \[ED\] by analyzing responses to the mSCOFF questionnaire (score ≥ 2) and/or problematic eating behaviors \[PEB\] by analyzing responses to the QACD questionnaire (score ≥ 20).
Time frame: 6 months after the inclusion
Prevalence of eating disorders (EDs)
Prevalence of EDs (mSCOFF score ≥ 2 and QACD ≥ 20)
Time frame: 6 months after the inclusion
Clinical characteristics at inclusion
Measurement of clinical characteristics at inclusion: age
Time frame: 6 months after the inclusion
Clinical characteristics at inclusion
Measurement of clinical characteristics at inclusion: sex
Time frame: 6 months after the inclusion
Clinical characteristics at inclusion
Measurement of clinical characteristics at inclusion: weight in kg and height in cm which will be combined to calculate the BMI (kg/m²)
Time frame: 6 months after the inclusion
Clinical characteristics at inclusion
Measurement of clinical characteristics at inclusion: medical history
Time frame: 6 months after the inclusion
Clinical characteristics at inclusion
Measurement of clinical characteristics at inclusion: treatments
Time frame: 6 months after the inclusion
Description of glycemic control at inclusion
Measurement of basic glycemic control : Hba1c average
Time frame: 6 months after the inclusion
Description of variability indicators at inclusion
Measurement of basic glycemic variability parameters : continuous glucose measurement data
Time frame: 6 months after the inclusion
Evolution of biological parameters of glycemic variability between the inclusion visit and the follow-up visits
Measurement of the variation in blood glycemic variability (continuous glucose measurement data) parameters between the inclusion visit and the different follow-up visits (3 months and 6 months)
Time frame: 6 months after the inclusion
Evolution of biological control parameters variability between the inclusion visit and the follow-up visits
Measurement of the variation in blood control parameters variability (HbA1c) between the inclusion visit and the different follow-up visits (3 months and 6 months)
Time frame: 6 months after the inclusion
Evolution of BMI between inclusion and follow-up visits
Change in BMI between the baseline visit and the 3-month and 6-month follow-up visits
Time frame: 6 months after the inclusion
Evolution of body weight between inclusion and follow-up visits
Change in body weight between the baseline visit and the 3-month and 6-month follow-up visits
Time frame: 6 months after the inclusion
Change in questionnaires scores between baseline and follow-up
Change in mSCOFF (Sick, control, one stone, fat, food) scores between the baseline visit and the 6-month follow-up visit
Time frame: 6 months after the inclusion
Change in questionnaires scores between baseline and follow-up
Change in QACD (questionnaires of attitudes and behaviors related to diabetes management) scores between the baseline visit and the 6-month follow-up visit
Time frame: 6 months after the inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.
Of 61 non-industry observational studies under Feeding and Eating Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 95. This study's planned 17 months is below that.
Counting every sponsor, half of 64 studies reached it within 42 months; a quarter within 18 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Feeding and Eating Disorders →
University Hospital, Toulouse →